Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5,325 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Randomized phase II adjuvant trial of dose-dense docetaxel before or after doxorubicin plus cyclophosphamide in axillary node-positive breast cancer.
Puhalla S, Mrozek E, Young D, Ottman S, McVey A, Kendra K, Merriman NJ, Knapp M, Patel T, Thompson ME, Maher JF, Moore TD, Shapiro CL. Puhalla S, et al. Among authors: young d. J Clin Oncol. 2008 Apr 1;26(10):1691-7. doi: 10.1200/JCO.2007.14.3941. Epub 2008 Mar 3. J Clin Oncol. 2008. PMID: 18316792 Clinical Trial.
A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab.
Mani A, Roda J, Young D, Caligiuri MA, Fleming GF, Kaufman P, Brufsky A, Ottman S, Carson WE 3rd, Shapiro CL. Mani A, et al. Among authors: young d. Breast Cancer Res Treat. 2009 Sep;117(1):83-9. doi: 10.1007/s10549-008-0251-7. Epub 2008 Dec 3. Breast Cancer Res Treat. 2009. PMID: 19051009 Free PMC article. Clinical Trial.
A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: analysis of sustained interferon gamma production in a subset of patients.
Parihar R, Nadella P, Lewis A, Jensen R, De Hoff C, Dierksheide JE, VanBuskirk AM, Magro CM, Young DC, Shapiro CL, Carson WE 3rd. Parihar R, et al. Clin Cancer Res. 2004 Aug 1;10(15):5027-37. doi: 10.1158/1078-0432.CCR-04-0265. Clin Cancer Res. 2004. PMID: 15297404 Clinical Trial.
A dose-finding and pharmacodynamic study of bortezomib in combination with weekly paclitaxel in patients with advanced solid tumors.
Ramaswamy B, Bekaii-Saab T, Schaaf LJ, Lesinski GB, Lucas DM, Young DC, Ruppert AS, Byrd JC, Culler K, Wilkins D, Wright JJ, Grever MR, Shapiro CL. Ramaswamy B, et al. Among authors: young dc. Cancer Chemother Pharmacol. 2010 May;66(1):151-8. doi: 10.1007/s00280-009-1145-z. Epub 2009 Sep 23. Cancer Chemother Pharmacol. 2010. PMID: 19774377 Free PMC article. Clinical Trial.
A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies.
Bekaii-Saab TS, Roda JM, Guenterberg KD, Ramaswamy B, Young DC, Ferketich AK, Lamb TA, Grever MR, Shapiro CL, Carson WE 3rd. Bekaii-Saab TS, et al. Among authors: young dc. Mol Cancer Ther. 2009 Nov;8(11):2983-91. doi: 10.1158/1535-7163.MCT-09-0820. Epub 2009 Nov 3. Mol Cancer Ther. 2009. PMID: 19887543 Free PMC article. Clinical Trial.
Phase I study of the sequential combination of interleukin-12 and interferon alfa-2b in advanced cancer: evidence for modulation of interferon signaling pathways by interleukin-12.
Eisenbeis CF, Lesinski GB, Anghelina M, Parihar R, Valentino D, Liu J, Nadella P, Sundaram P, Young DC, Sznol M, Walker MJ, Carson WE 3rd. Eisenbeis CF, et al. Among authors: young dc. J Clin Oncol. 2005 Dec 1;23(34):8835-44. doi: 10.1200/JCO.2005.02.1691. J Clin Oncol. 2005. PMID: 16314644 Clinical Trial.
5,325 results